- TRADE NAME: Braftovi (Array Biopharma Inc)
- INDICATIONS: in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation
- CLASS: BRAF inhibitor, Kinase inhibitor
- HALF-LIFE: 3.5 hours
- FDA APPROVAL DATE: 06/27/2018
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: can cause fetal harm
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 11/27/2024
